Discovery Genomics
Discovery Genomics, founded in 2022, is a genomics company focused on advancing precision health through whole-genome sequencing and proprietary analytics.
Profile
Discovery Genomics provides genomic sequencing and analytics to advance precision health and cancer research.
Discovery Genomics, founded in 2022, is a genomics company focused on advancing precision health through whole-genome sequencing and proprietary analytics. The company emerged from a collaboration between bioinformatics experts and researchers at the Broad Institute, aiming to unlock new insights in cancer genomics and rare diseases. Discovery Genomics has positioned itself as a key player in the rapidly evolving genomics market, leveraging its proprietary technology to analyze large-scale genomic datasets.
In 2025, the company reported revenues of $427 million, driven by a 54% increase in exome and genome revenue. Its headcount stands at approximately 1,200 employees, with a strong emphasis on R&D and clinical applications. The company’s recent focus has been on expanding its oncology solutions portfolio, including partnerships with leading cancer research institutions.
Discovery Genomics’ financial trajectory remains robust, with 2026 revenue guidance projecting $540-$555 million, supported by a 33-35% growth in exome and genome testing. The company’s acquisition of Fabric Genomics in 2025, though initially promising, has faced challenges, leading to a significant impairment charge in Q1 2026. Despite this setback, Discovery Genomics continues to innovate, with its AI-driven platform, GeneDx Infinity, playing a central role in its strategy.
Who buys this
- Clinical diagnostics labs
- Pharmaceutical companies
- Academic research institutions
- Hospitals and healthcare providers
- Biotech firms
Strengths and what to watch
Strengths
- Strong revenue growth in exome and genome testing, up 54% in 2025
- Proprietary AI-driven platform, GeneDx Infinity, for rare disease diagnostics
- Strategic partnerships with leading cancer research institutions
Watch for
- Significant impairment charge of $31.2 million related to Fabric Genomics acquisition in 2026
- Decline in average reimbursement rate (ARR) by $200 in Q1 2026
- Increased competition in the genomics market from established players like Illumina
Recent moves
Key Information
- Founded
- 2022
Frequently Asked Questions
What does Discovery Genomics do?
Discovery Genomics provides whole-genome sequencing and analytics to advance precision health and cancer research. Founded in 2022, it focuses on rare diseases and oncology, leveraging its AI-driven GeneDx Infinity platform. The company serves clinical labs, pharma firms, and research institutions with proprietary genomic data analysis.
How has Discovery Genomics performed financially?
Discovery Genomics reported $427 million revenue in 2025, with 54% growth in exome and genome testing. 2026 guidance projects $540-$555 million revenue. However, a $31.2 million impairment charge from its Fabric Genomics acquisition impacted Q1 2026 results, alongside a $200 decline in average reimbursement rates.
What is GeneDx Infinity?
GeneDx Infinity is Discovery Genomics' proprietary AI-driven platform for rare disease diagnostics and genomic analysis. It plays a central role in the company's strategy, enabling large-scale data interpretation for clinical and research applications, particularly in cancer genomics and precision health solutions.
Who uses Discovery Genomics' services?
Discovery Genomics serves clinical diagnostics labs, pharmaceutical companies, academic research institutions, hospitals, and biotech firms. Its solutions support precision health initiatives, cancer research, and rare disease diagnostics through advanced genomic sequencing and analytics tailored for diverse healthcare and research needs.
What challenges does Discovery Genomics face?
Discovery Genomics faces a $31.2 million impairment charge from its Fabric Genomics acquisition, declining reimbursement rates, and competition from firms like Illumina. Despite strong revenue growth, market dynamics and integration challenges pose risks to its expansion in clinical genomics and oncology solutions.
What are Discovery Genomics' recent developments?
In 2025, Discovery Genomics acquired Fabric Genomics and launched oncology-focused partnerships. However, 2026 brought financial setbacks, including impairment charges and a securities class action after a 49% stock drop. The company continues expanding its GeneDx Infinity platform while navigating market challenges.
Sources
- www.prnewswire.com — Securities class action and financial challenges in 2026
- www.sec.gov — 2025 financial results and 2026 guidance
- www.prnewswire.com — Market dynamics and competition in genomics
- www.prnewswire.com — Expansion into clinical oncology solutions